Pfizer's monoclonal antibody, ponsegromab, shows promising results in midstage trials for cancer cachexia, a condition affecting 9 million people globally.

Pfizer's monoclonal antibody, ponsegromab, has shown promising results in midstage trials for cancer cachexia, a serious condition causing weight and appetite loss in cancer patients. Improvements were noted in body weight, muscle mass, and quality of life. If successful, ponsegromab could be the first specific treatment for this condition, which impacts 9 million people globally and has a high mortality rate. Pfizer plans to pursue late-stage development and aims for studies in 2025.

September 14, 2024
13 Articles

Further Reading